sirolimus and Leukemia--Myelomonocytic--Acute

sirolimus has been researched along with Leukemia--Myelomonocytic--Acute* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and Leukemia--Myelomonocytic--Acute

Article	Year
Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells. Leukemia research, 2012, Volume: 36, Issue:6 CCAAT/enhancer binding protein alpha (C/EBPα) induction induces monocytic differentiation even in acute myeloid leukaemia (AML). In this study, the induction/activation of C/EBPα in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor. Combining these agents increased PU.1, C/EBPε and C/EBPα expression, increased the p42/p30 C/EBPα ratio, and decreased C/EBPα phosphorylation at serine 21, and was accompanied by growth inhibition, induction of CD11b expression and apoptosis in AML cell lines. Thus, agents that induce sufficient levels of C/EBPα expression might be useful in treating AML. Topics: Apoptosis; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; Everolimus; Female; Gene Expression Regulation, Leukemic; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Monocytes; Phosphorylation; RNA Processing, Post-Transcriptional; Sirolimus; Tretinoin; U937 Cells	2012

Article

Year

Post-transcriptional modulation of C/EBPα prompts monocytic differentiation and apoptosis in acute myelomonocytic leukaemia cells.

Leukemia research, 2012, Volume: 36, Issue:6

CCAAT/enhancer binding protein alpha (C/EBPα) induction induces monocytic differentiation even in acute myeloid leukaemia (AML). In this study, the induction/activation of C/EBPα in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor. Combining these agents increased PU.1, C/EBPε and C/EBPα expression, increased the p42/p30 C/EBPα ratio, and decreased C/EBPα phosphorylation at serine 21, and was accompanied by growth inhibition, induction of CD11b expression and apoptosis in AML cell lines. Thus, agents that induce sufficient levels of C/EBPα expression might be useful in treating AML.

Topics: Apoptosis; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; Everolimus; Female; Gene Expression Regulation, Leukemic; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Monocytes; Phosphorylation; RNA Processing, Post-Transcriptional; Sirolimus; Tretinoin; U937 Cells

2012